Immunotherapy rechallenge is a potential safety net for patients
Rechallenge with PD-1/PD-L1 inhibitors after a (un)planned interruption may offer a potential safety net for patients with disease progression. At ESMO Congress 2019, results from a study systematically investigating this approach for the first time…
Read More